Subgroup analyses also revealed that combination therapy using SBRT or SRS and PD‐1/PD‐L1 inhibitors may be more effective than combination therapy using conventional RT and PD‐1/PD‐L1 inhibitors in patients with advanced NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.